Immunovant, Inc.
IMVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764013
In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Immunovant, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 197 | 1 | 182 | −14 |
| Shares | 74.8M | 4.92M | 79.2M | +9.37M (+13.4%) |
| Value | $1.97B | $129.8M | $2.26B | +$415.3M (+22.5%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (21)
Institutions that held Immunovant, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 5,053,150 | $144.1M | 0.00% |
| Hood River Capital Management LLC | 1,143,567 | $32.6M | 0.53% |
| Federated Hermes, Inc. | 154,192 | $4.40M | 0.01% |
| Marshall Wace, LLP | 114,104 | $3.25M | 0.00% |
| Man Group plc | 109,390 | $3.12M | 0.01% |
| SEI Investments Co | 38,915 | $1.11M | 0.00% |
| Nicholas Investment Partners, LP | 33,103 | $943.8K | 0.09% |
| Intech Investment Management LLC | 21,825 | $622.2K | 0.01% |
| Hudson Bay Capital Management LP | 20,000 | $570.2K | 0.00% |
| B. Metzler seel. Sohn & Co. Holding AG | 18,136 | $517.1K | 0.01% |
| Advantage Alpha Capital Partners LP | 14,975 | $426.9K | 0.10% |
| Superstring Capital Management LP | 12,447 | $354.9K | 0.32% |
| Pictet & Cie (Europe) SA | 9,168 | $261.4K | 0.01% |
| Wolverine Trading, LLC | 7,372 | $206.6K | 0.01% |
| Acadian Asset Management LLC | 3,397 | $96.0K | 0.00% |
| Aster Capital Management (DIFC) Ltd | 291 | $8.30K | 0.00% |
| Sterling Capital Management LLC | 58 | $1.65K | 0.00% |
| Bessemer Group Inc | 50 | $1.00K | 0.00% |
| Bryn Mawr Trust Co | 24 | $684 | 0.00% |
| Capital Performance Advisors LLP | 3 | $86 | 0.00% |
| Reuter James Wealth Management, LLC | 1 | $29 | 0.00% |
Sold out (35)
Institutions that held Immunovant, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
Not filed for Q3 2024 yet (1)
Institutions that held Immunovant, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 4,916,127 | $129.8M |